Literature DB >> 20854024

Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus.

Andreas Pichlmair1, Matthias Habjan, Hermann Unger, Friedemann Weber.   

Abstract

Rift Valley fever virus (RVFV), a member of the family Bunyaviridae, regularly accounts for large and severe outbreaks among humans and livestock in Africa and Arabia. Therefore, safe and efficient vaccines are highly needed. Here, we report the production of recombinant virus-like particles (VLPs) that, in addition to their similarity to RVFV particles, are able to express the viral nucleocapsid (N) gene. A single inoculation of 1 × 10(6) of these N-VLPs was sufficient to protect 100% of mice from infection with a lethal dose of 1 × 10(5) PFU of RVFV. Our study demonstrates that N-VLPs can be considered as a safe and efficient vaccine against the emerging pathogen RVFV, and that VLPs that actively produce a viral antigen may be considered a strategy to improve the immunogenicity of VLPs in general.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854024     DOI: 10.1089/vbz.2009.0248

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  13 in total

1.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 2.  Rift valley fever: recent insights into pathogenesis and prevention.

Authors:  Hani Boshra; Gema Lorenzo; Núria Busquets; Alejandro Brun
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

Review 3.  Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Authors:  Kaori Terasaki; Breanna R Tercero; Shinji Makino
Journal:  Virus Res       Date:  2015-05-27       Impact factor: 3.303

Review 4.  Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Authors:  Darryl Falzarano; Heinz Feldmann
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090

5.  Functional analysis of Rift Valley fever virus NSs encoding a partial truncation.

Authors:  Jennifer A Head; Birte Kalveram; Tetsuro Ikegami
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

6.  Rift Valley Fever Vaccine Development, Progress and Constraints.

Authors:  Jeroen Kortekaas; James Zingeser; Peter de Leeuw; Stephane de La Rocque; Hermann Unger; Rob J M Moormann
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

7.  Development of a novel, single-cycle replicable rift valley Fever vaccine.

Authors:  Shin Murakami; Kaori Terasaki; Sydney I Ramirez; John C Morrill; Shinji Makino
Journal:  PLoS Negl Trop Dis       Date:  2014-03-20

8.  The Rift Valley fever accessory proteins NSm and P78/NSm-GN are distinct determinants of virus propagation in vertebrate and invertebrate hosts.

Authors:  Felix Kreher; Carole Tamietti; Céline Gommet; Laurent Guillemot; Myriam Ermonval; Anna-Bella Failloux; Jean-Jacques Panthier; Michèle Bouloy; Marie Flamand
Journal:  Emerg Microbes Infect       Date:  2014-10-01       Impact factor: 7.163

Review 9.  Current Status of Rift Valley Fever Vaccine Development.

Authors:  Bonto Faburay; Angelle Desiree LaBeaud; D Scott McVey; William C Wilson; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2017-09-19

10.  The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses.

Authors:  Weidong Xu; Douglas M Watts; Margaret C Costanzo; Xiaolei Tang; Leon A Venegas; Feng Jiao; Alessandro Sette; John Sidney; Andrew K Sewell; Linda Wooldridge; Shinji Makino; John C Morrill; Clarence J Peters; June Kan-Mitchell
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.